FDA Advisory Committee Votes Against Gefapixant for Chronic Cough in Adult Patients

This news from the FDA followed a resubmission after the FDA’s complete response letter for the P2X3 receptor antagonist’s use in refractory chronic cough and unexplained cough.

Related Keywords

Mark Courey ,Drug Administration ,Center At Mount Sinai ,Merck Co ,Grabscheid Voice ,Swallowing Center ,Mount Sinai ,Response Letter ,Chronic Cough Drug Candidate ,Cough ,Fda ,Gegapixant ,Advisory ,